Cargando…

Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study

BACKGROUND: Direct acting antivirals for hepatitis C virus have shown dramatic results in clinical trials. However, their effectiveness has yet to be demonstrated within observational cohorts which lack exclusion criteria found in randomized control trials. AIM: To determine the effectiveness of das...

Descripción completa

Detalles Bibliográficos
Autores principales: Leventer-Roberts, Maya, Hammerman, Ariel, Brufman, Ilan, Hoshen, Moshe, Braun, Marius, Ashur, Yaffa, Lieberman, Nicky, Balicer, Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501432/
https://www.ncbi.nlm.nih.gov/pubmed/28686590
http://dx.doi.org/10.1371/journal.pone.0176858
_version_ 1783248781407420416
author Leventer-Roberts, Maya
Hammerman, Ariel
Brufman, Ilan
Hoshen, Moshe
Braun, Marius
Ashur, Yaffa
Lieberman, Nicky
Balicer, Ran
author_facet Leventer-Roberts, Maya
Hammerman, Ariel
Brufman, Ilan
Hoshen, Moshe
Braun, Marius
Ashur, Yaffa
Lieberman, Nicky
Balicer, Ran
author_sort Leventer-Roberts, Maya
collection PubMed
description BACKGROUND: Direct acting antivirals for hepatitis C virus have shown dramatic results in clinical trials. However, their effectiveness has yet to be demonstrated within observational cohorts which lack exclusion criteria found in randomized control trials. AIM: To determine the effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir in achieving sustained virological response. METHODS: Retrospective observational cohort study of all Clalit Health Services members with hepatitis C virus genotype 1 who were dispensed dasabuvir/ombitasvir/paritaprevir/ritonavir from January 1, 2015 to-November 31, 2015. RESULTS: There were 564 participants during the study period. The average age was 61.9 years, 52.0% were male, and 61.5% were born Eastern/Central Europe or Central Asia. The prevalence of diabetes was 31.7% and 70.3% were overweight/obese. Cirrhosis was present in 41.0% of participants, of whom 52.8% had stage 4 fibrosis. Of the cohort, 416 (74.8%) had follow-up viral load testing at 10 or more weeks after the end of treatment. We report a sustained virological response of 98.8% among those tested. CONCLUSIONS: Treatment with dasabuvir/ombitasvir/paritaprevir/ritonavir demonstrated a near universal effectiveness in achieving a sustained virological response among HCV patients in a large cohort.
format Online
Article
Text
id pubmed-5501432
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-55014322017-07-25 Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study Leventer-Roberts, Maya Hammerman, Ariel Brufman, Ilan Hoshen, Moshe Braun, Marius Ashur, Yaffa Lieberman, Nicky Balicer, Ran PLoS One Research Article BACKGROUND: Direct acting antivirals for hepatitis C virus have shown dramatic results in clinical trials. However, their effectiveness has yet to be demonstrated within observational cohorts which lack exclusion criteria found in randomized control trials. AIM: To determine the effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir in achieving sustained virological response. METHODS: Retrospective observational cohort study of all Clalit Health Services members with hepatitis C virus genotype 1 who were dispensed dasabuvir/ombitasvir/paritaprevir/ritonavir from January 1, 2015 to-November 31, 2015. RESULTS: There were 564 participants during the study period. The average age was 61.9 years, 52.0% were male, and 61.5% were born Eastern/Central Europe or Central Asia. The prevalence of diabetes was 31.7% and 70.3% were overweight/obese. Cirrhosis was present in 41.0% of participants, of whom 52.8% had stage 4 fibrosis. Of the cohort, 416 (74.8%) had follow-up viral load testing at 10 or more weeks after the end of treatment. We report a sustained virological response of 98.8% among those tested. CONCLUSIONS: Treatment with dasabuvir/ombitasvir/paritaprevir/ritonavir demonstrated a near universal effectiveness in achieving a sustained virological response among HCV patients in a large cohort. Public Library of Science 2017-07-07 /pmc/articles/PMC5501432/ /pubmed/28686590 http://dx.doi.org/10.1371/journal.pone.0176858 Text en © 2017 Leventer-Roberts et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Leventer-Roberts, Maya
Hammerman, Ariel
Brufman, Ilan
Hoshen, Moshe
Braun, Marius
Ashur, Yaffa
Lieberman, Nicky
Balicer, Ran
Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study
title Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study
title_full Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study
title_fullStr Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study
title_full_unstemmed Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study
title_short Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study
title_sort effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis c virus in clinical practice: a population-based observational study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501432/
https://www.ncbi.nlm.nih.gov/pubmed/28686590
http://dx.doi.org/10.1371/journal.pone.0176858
work_keys_str_mv AT leventerrobertsmaya effectivenessofdasabuvirombitasvirparitaprevirritonavirforhepatitiscvirusinclinicalpracticeapopulationbasedobservationalstudy
AT hammermanariel effectivenessofdasabuvirombitasvirparitaprevirritonavirforhepatitiscvirusinclinicalpracticeapopulationbasedobservationalstudy
AT brufmanilan effectivenessofdasabuvirombitasvirparitaprevirritonavirforhepatitiscvirusinclinicalpracticeapopulationbasedobservationalstudy
AT hoshenmoshe effectivenessofdasabuvirombitasvirparitaprevirritonavirforhepatitiscvirusinclinicalpracticeapopulationbasedobservationalstudy
AT braunmarius effectivenessofdasabuvirombitasvirparitaprevirritonavirforhepatitiscvirusinclinicalpracticeapopulationbasedobservationalstudy
AT ashuryaffa effectivenessofdasabuvirombitasvirparitaprevirritonavirforhepatitiscvirusinclinicalpracticeapopulationbasedobservationalstudy
AT liebermannicky effectivenessofdasabuvirombitasvirparitaprevirritonavirforhepatitiscvirusinclinicalpracticeapopulationbasedobservationalstudy
AT balicerran effectivenessofdasabuvirombitasvirparitaprevirritonavirforhepatitiscvirusinclinicalpracticeapopulationbasedobservationalstudy